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Introduction
Juvenile Idiopathic Arthritis (JIA) is one of the most
common chronic pediatric rheumatic diseases (PRD). As
is the case for most PRD’s, evidence-based guidelines
are sparse and management is based to great extent on
physician’s experience. Moreover, there are differences
between nations regarding availability and financing of
biological therapies. Consequently, treatment regimens
differ throughout Europe. In 2012, a European initiative
called SHARE (Single Hub and Access point for pedia-
tric Rheumatology in Europe) was launched to optimize
and disseminate diagnostic and management regimens
in Europe for children and young adults with rheumatic
diseases.
Objectives
To provide evidence based recommendations for diag-
nosis and treatment of JIA.
Methods
Evidence based recommendations were developed using
the European League Against Rheumatism (EULAR)
standard operating procedure [1]. An expert committee
was instituted, consisting of pediatric rheumatologists
from across Europe with expertise in JIA. The expert
committee defined search terms for the systematic lit-
erature review. Two independent experts scored articles
for validity and level of evidence. Recommendations
derived from the literature were evaluated by an online
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The value of MRI in the diagnosis arthritis Steroids (locally and systemically administered)
The value of ultrasound in the diagnosis of arthritis DMARDS
Biomarkers for diagnosis of JIA Biologicals
Diagnosis of complications Treatment of complications
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survey. Those with less than 80% agreement during the
online survey were reformulated. Subsequently, all
recommendations were discussed by the experts at a
consensus meeting using the nominal group technique
[2]. Recommendations were accepted if more than 80%
agreement was reached.
Results
The literature search yielded 4723 articles, of which 174
were considered relevant. The included articles were
scored for validity and level of evidence. Recommenda-
tions were formulated based on the valid papers and
were discussed and adjusted where needed during the
consensus meeting. In total, 10 recommendations for
diagnosis and 31 for treatment were accepted with more
than 80% agreement. Topics covered for diagnosis and
for treatment are shown in Table 1.
Conclusion
The SHARE initiative provides recommendations for
diagnosis and treatment of JIA and thereby facilitates
improvement and uniformity of care throughout Europe.
In the subsequent phase of the project, best practices
identified from literature will be completed with the
‘experts opinion’ in order to formulate diagnostic and
management guidelines as best practices for care of JIA
patients throughout Europe.
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